Atty's Docket:~~101195-54~~
DORKEN et al.,

AMENDMENT TO THE SPECIFICATION

Please amend the previously submitted BRIEF DESCRIPTION OF THE DRAWINGS, as follows:

– Brief Description of the Drawings

Fig. 1 - flow chart illustrating the expression cassette;

Fig. 2 - flow chart illustrating the simple approach with which therapeutic genes may be removed from, or added to the plasmid. ~~a kind of "box-of-bricks" system in which the therapeutic genes can be replaced with a low amount of effort;~~

Fig. 3 - chart illustrating the generation of a recombinant adenoviral plasmid ~~plasmide~~ containing the expressing cassette by homologous recombination in the BJ cells;

Fig. 4a- graft showing the constitutive promoter leading to a continuous increase of the serum content of hAAT; and

Fig. 4b- graft showing the Ad vector with the YB-a promoter leading to a temporarily very high expression with a maximum serum content of hAAT on the third day.

On page 6, delete the first paragraph, from *pCR2.1* to *(see Fig. 2)* with the following replacement paragraph.

pCR2.1 vector of Invitrogen and nucleotide 453-2150 of the YB-1 promoter sequence, gene bank Acc.# X96666). These two elements represent the expression cassette (see Fig. 1). In this, the YB-1 promoter is cloned into an ~~MSC~~ **MCS** of a vector adapted specifically for this purpose in such a way that various therapeutic genes can be put under the control of the promoter without the MCS having to be adapted again. This is a MCS containing a group of specifically selected enzyme restriction sites.

These restriction sites are to permit a quick and uncomplicated exchange of the therapeutic genes into the expression cassette "downstream" of the promoter. Additional changes to the remaining vector and to the YB-1 promoter already existing are avoided in this way. Thus, there results a simple ~~kind of "box of bricks"~~ system in which the therapeutic genes can be replaced with little ~~a low amount of~~ effort (see Fig. 2).

On page 8, please delete the second and third paragraphs, and replace with the following amended second and third paragraphs, respectively.

The constitutive promoter led to a continuous increase of the serum content of hAAT (Fig. 4A). In contrast ~~contract~~, the Ad vector with the YB-1 promoter led to a temporarily very high expression with a maximum serum content of hAAT on the third day (Fig. 4B).

1.0x10^9 pfu AdRSV.hAAT (A) or AdYB-1.hAAT (B) was injected intravenously into SCID mice (n=3 for A and B). The serum content of human alpha 1-antitrypsin (hAAT) was determined by means of ELISA. Each bar graph in Fig. 4A and 4B represents the serum hAAT level of a single mouse at the indicated times post infection. Three mice at each time point were tested.